PEAK6 Group
ESPR icon

PEAK6 Group’s Esperion Therapeutics ESPR Stock Holding History

PEAK6 Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,615
Closed -$66K – 4890
2015
Q3 		$62K Buy
2,615
+2,115
+423% +$133K ﹤0.01% 4574
2015
Q2 		$41K Buy
+500
New +$48.9K ﹤0.01% 4632

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

PEAK6 Group's ESPR Position: Q4 2015 in Review

PEAK6 Group sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 2,615 shares — an estimated $66K sold.

PEAK6 Group first reported a position in ESPR in Q2 2015 and held it in 2 quarters. The position peaked at $62K in Q3 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • PEAK6 Group reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 2,615 Esperion Therapeutics shares in Q4 2015, an estimated $66K.
  • PEAK6 Group first reported a position in Esperion Therapeutics in Q2 2015 and held it in 2 quarters.
  • PEAK6 Group's Esperion Therapeutics position peaked at $62K in Q3 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.